Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 47

1.

Low-dose total skin electron beam therapy: Quality of life improvement and clinical impact of maintenance and adjuvant treatment in patients with mycosis fungoides or Sezary syndrome.

Elsayad K, Kroeger K, Greve B, Moustakis C, Assaf C, Stadler R, Lenz G, Weishaupt C, Eich HT.

Strahlenther Onkol. 2019 Oct 7. doi: 10.1007/s00066-019-01517-7. [Epub ahead of print]

PMID:
31591658
2.

Activation of human vascular endothelium in melanoma metastases induces ICAM-1 and E-selectin expression and results in increased infiltration with effector lymphocytes.

Weishaupt C, Steinert M, Brunner G, Schulze HJ, Fuhlbrigge RC, Goerge T, Loser K.

Exp Dermatol. 2019 Aug 24. doi: 10.1111/exd.14023. [Epub ahead of print]

PMID:
31444891
3.

Evidence and impact of neutrophil extracellular traps in malignant melanoma.

Schedel F, Mayer-Hain S, Pappelbaum KI, Metze D, Stock M, Goerge T, Loser K, Sunderkötter C, Anton Luger T, Weishaupt C.

Pigment Cell Melanoma Res. 2019 Aug 12. doi: 10.1111/pcmr.12818. [Epub ahead of print]

PMID:
31402559
4.

Combination of denosumab and immune checkpoint inhibition: experience in 29 patients with metastatic melanoma and bone metastases.

Angela Y, Haferkamp S, Weishaupt C, Ugurel S, Becker JC, Oberndörfer F, Alar V, Satzger I, Gutzmer R.

Cancer Immunol Immunother. 2019 Jul;68(7):1187-1194. doi: 10.1007/s00262-019-02353-5. Epub 2019 Jun 11.

PMID:
31187176
5.

Characteristics, risk factors and treatment reality in livedoid vasculopathy - a multicentre analysis.

Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T.

J Eur Acad Dermatol Venereol. 2019 Sep;33(9):1784-1791. doi: 10.1111/jdv.15639. Epub 2019 May 14.

PMID:
31009111
6.

Real-World Use of Talimogene Laherparepvec in German Patients with Stage IIIB to IVM1a Melanoma: A Retrospective Chart Review and Physician Survey.

Mohr P, Haferkamp S, Pinter A, Weishaupt C, Huber MA, Downey G, Öhrling K, Loquai C, Louie KS.

Adv Ther. 2019 Jan;36(1):101-117. doi: 10.1007/s12325-018-0850-6. Epub 2018 Dec 7.

7.

The efficacy of re-challenge with BRAF inhibitors after previous progression to BRAF inhibitors in melanoma: A retrospective multicenter study.

Tietze JK, Forschner A, Loquai C, Mitzel-Rink H, Zimmer L, Meiss F, Rafei-Shamsabadi D, Utikal J, Bergmann M, Meier F, Kreuzberg N, Schlaak M, Weishaupt C, Pföhler C, Ziemer M, Fluck M, Rainer J, Heppt MV, Berking C.

Oncotarget. 2018 Sep 28;9(76):34336-34346. doi: 10.18632/oncotarget.26149. eCollection 2018 Sep 28.

8.

Exacerbation of mycosis fungoides leading to the diagnosis of chronic myelomonocytic leukemia.

Moritz RKC, Metze D, Wiebe S, Kerkhoff A, Berdel WE, Weishaupt C.

JAAD Case Rep. 2018 Mar 6;4(3):270-273. doi: 10.1016/j.jdcr.2017.09.023. eCollection 2018 Apr. No abstract available.

9.

Advanced cutaneous squamous cell carcinoma: A retrospective analysis of patient profiles and treatment patterns-Results of a non-interventional study of the DeCOG.

Hillen U, Leiter U, Haase S, Kaufmann R, Becker J, Gutzmer R, Terheyden P, Krause-Bergmann A, Schulze HJ, Hassel J, Lahner N, Wollina U, Ziller F, Utikal J, Hafner C, Ulrich J, Machens HG, Weishaupt C, Hauschild A, Mohr P, Pföhler C, Maurer J, Wolff P, Windemuth-Kieselbach C, Schadendorf D, Livingstone E; Dermatologic Cooperative Oncology Group (DeCOG).

Eur J Cancer. 2018 Jun;96:34-43. doi: 10.1016/j.ejca.2018.01.075. Epub 2018 Apr 14.

PMID:
29665511
10.

Clinical outcome of concomitant vs interrupted BRAF inhibitor therapy during radiotherapy in melanoma patients.

Hecht M, Meier F, Zimmer L, Polat B, Loquai C, Weishaupt C, Forschner A, Gutzmer R, Utikal JS, Goldinger SM, Geier M, Hassel JC, Balermpas P, Kiecker F, Rauschenberg R, Dietrich U, Clemens P, Berking C, Grabenbauer G, Schadendorf D, Grabbe S, Schuler G, Fietkau R, Distel LV, Heinzerling L.

Br J Cancer. 2018 Mar 20;118(6):785-792. doi: 10.1038/bjc.2017.489. Epub 2018 Feb 13.

11.

Complete durable remission of a fulminant primary cutaneous aggressive epidermotropic CD8+ cytotoxic T-cell lymphoma after autologous and allogeneic hematopoietic stem cell transplantation.

Plachouri KM, Weishaupt C, Metze D, Evers G, Berdel WE, Kempf W, Sunderkötter C, Stelljes M.

JAAD Case Rep. 2017 Apr 14;3(3):196-199. doi: 10.1016/j.jdcr.2017.02.004. eCollection 2017 May. No abstract available.

12.

Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.

Zimmer L, Apuri S, Eroglu Z, Kottschade LA, Forschner A, Gutzmer R, Schlaak M, Heinzerling L, Krackhardt AM, Loquai C, Markovic SN, Joseph RW, Markey K, Utikal JS, Weishaupt C, Goldinger SM, Sondak VK, Zager JS, Schadendorf D, Khushalani NI.

Eur J Cancer. 2017 Apr;75:47-55. doi: 10.1016/j.ejca.2017.01.009. Epub 2017 Feb 17.

PMID:
28214657
13.

Lack of protection from development of multiple melanomas by an injected melanocortin analogue in a combined high-risk MC1R/CDKN2A genotype patient.

Böhm M, Jagirdar K, Sturm RA, König S, Bauer J, Metze D, Luger TA, Weishaupt C.

J Eur Acad Dermatol Venereol. 2016 Oct;30(10):e65-e67. doi: 10.1111/jdv.13310. Epub 2015 Sep 2. No abstract available.

PMID:
26333485
14.

Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy.

Hofmann L, Forschner A, Loquai C, Goldinger SM, Zimmer L, Ugurel S, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Thomas I, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:190-209. doi: 10.1016/j.ejca.2016.02.025. Epub 2016 Apr 13.

PMID:
27085692
15.

Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy.

Zimmer L, Goldinger SM, Hofmann L, Loquai C, Ugurel S, Thomas I, Schmidgen MI, Gutzmer R, Utikal JS, Göppner D, Hassel JC, Meier F, Tietze JK, Forschner A, Weishaupt C, Leverkus M, Wahl R, Dietrich U, Garbe C, Kirchberger MC, Eigentler T, Berking C, Gesierich A, Krackhardt AM, Schadendorf D, Schuler G, Dummer R, Heinzerling LM.

Eur J Cancer. 2016 Jun;60:210-25. doi: 10.1016/j.ejca.2016.02.024. Epub 2016 Apr 13.

PMID:
27084345
16.

Anticoagulation with rivaroxaban for livedoid vasculopathy (RILIVA): a multicentre, single-arm, open-label, phase 2a, proof-of-concept trial.

Weishaupt C, Strölin A, Kahle B, Kreuter A, Schneider SW, Gerss J, Eveslage M, Drabik A, Goerge T.

Lancet Haematol. 2016 Feb;3(2):e72-9. doi: 10.1016/S2352-3026(15)00251-3. Epub 2016 Jan 16.

PMID:
26853646
17.

Total Skin Electron Beam for Primary Cutaneous T-cell Lymphoma.

Elsayad K, Kriz J, Moustakis C, Scobioala S, Reinartz G, Haverkamp U, Willich N, Weishaupt C, Stadler R, Sunderkötter C, Eich HT.

Int J Radiat Oncol Biol Phys. 2015 Dec 1;93(5):1077-86. doi: 10.1016/j.ijrobp.2015.08.041. Epub 2015 Sep 5.

PMID:
26581145
18.

Blocking neutrophil diapedesis prevents hemorrhage during thrombocytopenia.

Hillgruber C, Pöppelmann B, Weishaupt C, Steingräber AK, Wessel F, Berdel WE, Gessner JE, Ho-Tin-Noé B, Vestweber D, Goerge T.

J Exp Med. 2015 Jul 27;212(8):1255-66. doi: 10.1084/jem.20142076. Epub 2015 Jul 13.

19.

Radiosensitization by BRAF inhibitor therapy-mechanism and frequency of toxicity in melanoma patients.

Hecht M, Zimmer L, Loquai C, Weishaupt C, Gutzmer R, Schuster B, Gleisner S, Schulze B, Goldinger SM, Berking C, Forschner A, Clemens P, Grabenbauer G, Müller-Brenne T, Bauch J, Eich HT, Grabbe S, Schadendorf D, Schuler G, Keikavoussi P, Semrau S, Fietkau R, Distel LV, Heinzerling L.

Ann Oncol. 2015 Jun;26(6):1238-44. doi: 10.1093/annonc/mdv139. Epub 2015 Mar 11.

PMID:
25762352
20.

Ultraviolet B light attenuates the systemic immune response in central nervous system autoimmunity.

Breuer J, Schwab N, Schneider-Hohendorf T, Marziniak M, Mohan H, Bhatia U, Gross CC, Clausen BE, Weishaupt C, Luger TA, Meuth SG, Loser K, Wiendl H.

Ann Neurol. 2014 May;75(5):739-58. doi: 10.1002/ana.24165. Epub 2014 May 13.

PMID:
24771567
21.

Inhibition of the prohormone convertase subtilisin-kexin isoenzyme-1 induces apoptosis in human melanoma cells.

Weiß N, Stegemann A, Elsayed MAT, Schallreuter KU, Luger TA, Loser K, Metze D, Weishaupt C, Böhm M.

J Invest Dermatol. 2014 Jan;134(1):168-175. doi: 10.1038/jid.2013.282. Epub 2013 Jun 27.

22.

Functional and molecular genetic analyses of nine newly identified XPD-deficient patients reveal a novel mutation resulting in TTD as well as in XP/CS complex phenotypes.

Schäfer A, Gratchev A, Seebode C, Hofmann L, Schubert S, Laspe P, Apel A, Ohlenbusch A, Tzvetkov M, Weishaupt C, Oji V, Schön MP, Emmert S.

Exp Dermatol. 2013 Jul;22(7):486-9. doi: 10.1111/exd.12166.

PMID:
23800062
23.

New tools for assessing the individual risk of metastasis in renal cell carcinoma.

Herrmann E, Weishaupt C, Pöppelmann B, Hillgruber C, Pühse G, Krabbe LM, Feld M, Steinhoff M, Goerge T.

Clin Exp Metastasis. 2013 Feb;30(2):215-24. doi: 10.1007/s10585-012-9529-6. Epub 2012 Aug 23.

PMID:
22915161
24.

Evaluation of the German guideline for chronic pruritus: results of a retrospective study on 385 patients.

Siepmann D, Weishaupt C, Luger TA, Ständer S.

Dermatology. 2011;223(4):374-80. doi: 10.1159/000335782. Epub 2012 Feb 2.

PMID:
22301826
25.

Skeletal muscle involvement in early-onset mycosis fungoides.

Weishaupt C, Goerge T, Geissinger E, Kuhlmann T, Kurlemann G, Metze D, Sunderkötter C, Schiller M.

J Am Acad Dermatol. 2011 Jun;64(6):e118-20. doi: 10.1016/j.jaad.2010.09.726. No abstract available.

PMID:
21571157
26.

SOX2 and nestin expression in human melanoma: an immunohistochemical and experimental study.

Laga AC, Zhan Q, Weishaupt C, Ma J, Frank MH, Murphy GF.

Exp Dermatol. 2011 Apr;20(4):339-45. doi: 10.1111/j.1600-0625.2011.01247.x.

27.

RANK is expressed in metastatic melanoma and highly upregulated on melanoma-initiating cells.

Kupas V, Weishaupt C, Siepmann D, Kaserer ML, Eickelmann M, Metze D, Luger TA, Beissert S, Loser K.

J Invest Dermatol. 2011 Apr;131(4):944-55. doi: 10.1038/jid.2010.377. Epub 2011 Jan 27.

28.

Livedoid vasculopathy in a pediatric patient with elevated lipoprotein(a) levels: prompt response to continuous low-molecular-weight heparin.

Goerge T, Weishaupt C, Metze D, Nowak-Göttl U, Sunderkötter C, Steinhoff M, Schneider SW.

Arch Dermatol. 2010 Aug;146(8):927-8. doi: 10.1001/archdermatol.2010.177. No abstract available.

PMID:
20713839
29.

The embryonic morphogen, Nodal, is associated with channel-like structures in human malignant melanoma xenografts.

McAllister JC, Zhan Q, Weishaupt C, Hsu MY, Murphy GF.

J Cutan Pathol. 2010 Apr;37 Suppl 1:19-25. doi: 10.1111/j.1600-0560.2010.01503.x.

30.

Putative neuronal mechanisms of sensitive skin.

Ständer S, Schneider SW, Weishaupt C, Luger TA, Misery L.

Exp Dermatol. 2009 May;18(5):417-23. Review. Erratum in: Exp Dermatol. 2009 Dec;18(12):1096.

PMID:
19382311
31.

Treatment of chronic pruritus with the selective serotonin re-uptake inhibitors paroxetine and fluvoxamine: results of an open-labelled, two-arm proof-of-concept study.

Ständer S, Böckenholt B, Schürmeyer-Horst F, Weishaupt C, Heuft G, Luger TA, Schneider G.

Acta Derm Venereol. 2009;89(1):45-51. doi: 10.2340/00015555-0553.

32.

Dendritic cell activation by combined exposure to anti-CD40 plus interleukin (IL)-12 and IL-18 efficiently stimulates anti-tumor immunity.

Balkow S, Loser K, Krummen M, Higuchi T, Rothoeft T, Apelt J, Tuettenberg A, Weishaupt C, Beissert S, Grabbe S.

Exp Dermatol. 2009 Jan;18(1):78-87. doi: 10.1111/j.1600-0625.2008.00800.x. Epub 2008 Oct 22.

PMID:
19054060
33.

Identification of cells initiating human melanomas.

Schatton T, Murphy GF, Frank NY, Yamaura K, Waaga-Gasser AM, Gasser M, Zhan Q, Jordan S, Duncan LM, Weishaupt C, Fuhlbrigge RC, Kupper TS, Sayegh MH, Frank MH.

Nature. 2008 Jan 17;451(7176):345-9. doi: 10.1038/nature06489.

34.

Adhesion molecules in cutaneous immunity.

Fuhlbrigge RC, Weishaupt C.

Semin Immunopathol. 2007 Apr;29(1):45-57. Review.

PMID:
17621953
35.

T-cell distribution and adhesion receptor expression in metastatic melanoma.

Weishaupt C, Munoz KN, Buzney E, Kupper TS, Fuhlbrigge RC.

Clin Cancer Res. 2007 May 1;13(9):2549-56.

36.

Treatment of pustular psoriasis with infliximab.

Weishaupt C, Metze D, Luger TA, Ständer S.

J Dtsch Dermatol Ges. 2007 May;5(5):397-9. English, German.

PMID:
17451384
37.

Hydroxyl-radical-dependent DNA damage by ambient particulate matter from contrasting sampling locations.

Shi T, Duffin R, Borm PJ, Li H, Weishaupt C, Schins RP.

Environ Res. 2006 May;101(1):18-24. Epub 2005 Nov 17.

PMID:
16298360
38.

Systemic administration of a TLR7 ligand leads to transient immune incompetence due to peripheral-blood leukocyte depletion.

Gunzer M, Riemann H, Basoglu Y, Hillmer A, Weishaupt C, Balkow S, Benninghoff B, Ernst B, Steinert M, Scholzen T, Sunderkötter C, Grabbe S.

Blood. 2005 Oct 1;106(7):2424-32. Epub 2005 Jun 23.

PMID:
15976181
39.

Formation of PAH-DNA adducts after in vivo and vitro exposure of rats and lung cells to different commercial carbon blacks.

Borm PJ, Cakmak G, Jermann E, Weishaupt C, Kempers P, van Schooten FJ, Oberdörster G, Schins RP.

Toxicol Appl Pharmacol. 2005 Jun 1;205(2):157-67.

PMID:
15893543
40.

A spectrum of biophysical interaction modes between T cells and different antigen-presenting cells during priming in 3-D collagen and in vivo.

Gunzer M, Weishaupt C, Hillmer A, Basoglu Y, Friedl P, Dittmar KE, Kolanus W, Varga G, Grabbe S.

Blood. 2004 Nov 1;104(9):2801-9. Epub 2004 Jul 15.

PMID:
15256430
41.

Surface modification of quartz inhibits toxicity, particle uptake, and oxidative DNA damage in human lung epithelial cells.

Schins RP, Duffin R, Höhr D, Knaapen AM, Shi T, Weishaupt C, Stone V, Donaldson K, Borm PJ.

Chem Res Toxicol. 2002 Sep;15(9):1166-73.

PMID:
12230410
42.

Ambient exposure and nasal inflammation in adults and children--a preliminary analysis.

Polat D, Eberwein G, Becker A, Weishaupt C, Schins RP, Ranft U, Borm PJ.

Int J Hyg Environ Health. 2002 Apr;205(3):229-34.

PMID:
12040920
43.

Oxidant-induced DNA damage by quartz in alveolar epithelial cells.

Schins RP, Knaapen AM, Cakmak GD, Shi T, Weishaupt C, Borm PJ.

Mutat Res. 2002 May 27;517(1-2):77-86.

PMID:
12034310
44.

Two-step negative enrichment of CD4+ and CD8+ T cells from murine spleen via nylon wool adherence and an optimized antibody cocktail.

Gunzer M, Weishaupt C, Planelles L, Grabbe S.

J Immunol Methods. 2001 Dec 1;258(1-2):55-63.

PMID:
11684123
45.

Clara-cell hyperplasia after quartz and coal-dust instillation in rat lung.

Albrecht C, Adolf B, Weishaupt C, Höhr D, Zeitträger I, Friemann J, Borm PJ.

Inhal Toxicol. 2001 Mar;13(3):191-205.

PMID:
11295856
46.

Time-course analysis of type II cell hyperplasia and alveolar bronchiolization in rats treated with different particulates.

Friemann J, Albrecht C, Breuer P, Grover R, Weishaupt C.

Inhal Toxicol. 1999 Sep;11(9):837-54.

PMID:
10477445
47.

The early chick embryo as a model to evaluate cardiovascular effects of adrenaline and nicotine.

Rosenbruch M, Kniepen J, Weishaupt C.

Toxicol In Vitro. 1993 Jul;7(4):541-5.

PMID:
20732249

Supplemental Content

Loading ...
Support Center